Holloway R H, Kuljian B, Eshelman F, McCallum R W
Clin Pharmacol Ther. 1984 Feb;35(2):203-7. doi: 10.1038/clpt.1984.27.
We compared the effect of oral and intravenous ranitidine, a new H2-receptor antagonist, with that of cimetidine on pentagastrin-stimulated gastric acid secretion in normal subjects. Ranitidine in intravenous doses of 20, 60, and 100 mg and oral doses of 100, 150, and 200 mg inhibited acid secretion. Only the 100 mg iv ranitidine dose was substantially more effective than cimetidine. Comparable dose-related decreases in gastric secretory volume were observed. Acid inhibition correlated strongly (r = 0.90) with plasma ranitidine concentration, with the estimated plasma concentration producing 50% inhibition (IC50) being 95 ng/ml. Maximal acid inhibition achieved was 87.3%. We conclude that ranitidine is a potent inhibitor of gastric acid secretion and should be a valuable addition to the medical treatment of acid-peptic disease.
我们比较了新型H2受体拮抗剂雷尼替丁口服和静脉给药对正常受试者五肽胃泌素刺激胃酸分泌的影响,并与西咪替丁进行了对比。静脉注射剂量为20、60和100毫克以及口服剂量为100、150和200毫克的雷尼替丁均能抑制胃酸分泌。只有静脉注射100毫克雷尼替丁的剂量比西咪替丁显著更有效。观察到了类似的与剂量相关的胃分泌量减少情况。胃酸抑制作用与血浆雷尼替丁浓度密切相关(r = 0.90),产生50%抑制作用(IC50)的估计血浆浓度为95纳克/毫升。实现的最大胃酸抑制率为87.3%。我们得出结论,雷尼替丁是胃酸分泌的强效抑制剂,应该会成为酸相关性疾病药物治疗的一个有价值的补充。